Allosteric Binding-Mediated Suppression on Activity of G12D KRAS Recognized via Markov State Model and Communication Pathway
The Journal of Physical Chemistry B · 2026
DOI: 10.1021/acs.jpcb.5c07583 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Physical Chemistry B, 2026. Verfasst von Jianzhong Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Science, Shandong Jiaotong University, Jinan 250357, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Markov Chains, Oncogene Protein p21(ras). Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 111 Literaturangaben. Gefördert von: Shandong Jiaotong University, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Science, Shandong Jiaotong University, Jinan 250357, China.
- School of Information Engineering, Taizhou University, Taizhou, Jiangsu 225300, China.
ORCID-Profile: Jianzhong Chen, Jian Wang, Guodong Hu
Förderung
- Shandong Jiaotong University
- Natural Science Foundation of Shandong Province
Zitieren
APA
Chen, J., Wang, J., Wang, W., Zhao, L., Jin, H., & Hu, G. (2026). Allosteric Binding-Mediated Suppression on Activity of G12D KRAS Recognized via Markov State Model and Communication Pathway. The Journal of Physical Chemistry B. https://doi.org/10.1021/acs.jpcb.5c07583
Vancouver
Chen J, Wang J, Wang W, Zhao L, Jin H, Hu G. Allosteric Binding-Mediated Suppression on Activity of G12D KRAS Recognized via Markov State Model and Communication Pathway. The Journal of Physical Chemistry B. 2026. doi:10.1021/acs.jpcb.5c07583
BibTeX
@article{Chen2026,
author = {Chen, Jianzhong and Wang, Jian and Wang, Wei and Zhao, Lu and Jin, Handong and Hu, Guodong},
title = {Allosteric Binding-Mediated Suppression on Activity of G12D KRAS Recognized via Markov State Model and Communication Pathway},
journal = {The Journal of Physical Chemistry B},
year = {2026},
doi = {10.1021/acs.jpcb.5c07583}
}
EUVIMED